These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 33593595)

  • 41. Venous thromboembolism therapy with rivaroxaban in daily-care patients: Results from the Dresden NOAC registry.
    Keller L; Marten S; Hecker J; Sahin K; Tittl L; Beyer-Westendorf J
    Int J Cardiol; 2018 Apr; 257():276-282. PubMed ID: 29506708
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Design and rationale for the Japanese Registry of Rivaroxaban Effectiveness & Safety for the Prevention of Recurrence in Patients with Deep Vein Thrombosis and Pulmonary Embolism (J'xactly) study.
    Okumura Y; Fukuda I; Nakamura M; Yamada N; Takayama M; Maeda H; Yamashita T; Ikeda T; Mo M; Yamazaki T; Hirayama A;
    BMJ Open; 2018 Jun; 8(6):e020286. PubMed ID: 29934383
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cerebral Venous Thromboembolism in Antiphospholipid Syndrome Successfully Treated with the Combined Use of an Anti-Xa Inhibitor and Corticosteroid.
    Sugie M; Iizuka N; Shimizu Y; Ichikawa H
    Intern Med; 2015; 54(23):3051-6. PubMed ID: 26631891
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Oral direct factor Xa inhibitor versus enoxaparin for thromboprophylaxis after hip or knee arthroplasty: Systemic review, traditional meta-analysis, dose-response meta-analysis and network meta-analysis.
    Feng W; Wu K; Liu Z; Kong G; Deng Z; Chen S; Wu Y; Chen M; Liu S; Wang H
    Thromb Res; 2015 Dec; 136(6):1133-44. PubMed ID: 26498222
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Rivaroxaban limits complement activation compared with warfarin in antiphospholipid syndrome patients with venous thromboembolism.
    Arachchillage DR; Mackie IJ; Efthymiou M; Chitolie A; Hunt BJ; Isenberg DA; Khamashta M; Machin SJ; Cohen H
    J Thromb Haemost; 2016 Nov; 14(11):2177-2186. PubMed ID: 27541499
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Recurrent venous thromboembolism after discontinuation of rivaroxaban therapy in a patient with antiphospholipid syndrome.
    Yagi S; Nishiyama S; Abe T; Sata M
    BMJ Case Rep; 2019 Jan; 12(1):. PubMed ID: 30635311
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study.
    Alzghari SK; Seago SE; Garza JE; Hashimie YF; Baty KA; Evans MF; Shaver C; Herrington JD
    J Oncol Pharm Pract; 2018 Oct; 24(7):494-500. PubMed ID: 28714376
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rivaroxaban in the treatment of venous thromboembolism and the prevention of recurrences: a practical approach.
    Arcelus JI; Domènech P; Fernández-Capitan Mdel C; Guijarro R; Jiménez D; Jiménez S; Lozano FS; Monreal M; Nieto JA; Páramo JA
    Clin Appl Thromb Hemost; 2015 May; 21(4):297-308. PubMed ID: 25504999
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Utility of Rivaroxaban as Primary Venous Thromboprophylaxis in an Adult Trauma Population.
    Kingdon LK; Miller EM; Savage SA
    J Surg Res; 2019 Dec; 244():509-515. PubMed ID: 31336243
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In symptomatic isolated DVT, 12 wk vs. 6 wk of rivaroxaban reduced recurrent VTE at 24 mo.
    DeLoughery TG
    Ann Intern Med; 2023 Apr; 176(4):JC42. PubMed ID: 37011394
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications.
    Raskob GE; Spyropoulos AC; Zrubek J; Ageno W; Albers G; Elliott CG; Halperin J; Haskell L; Hiatt WR; Maynard GA; Peters G; Spiro T; Steg PG; Suh EY; Weitz JI
    Thromb Haemost; 2016 Jun; 115(6):1240-8. PubMed ID: 26842902
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Use of rivaroxaban in real-life treatment of venous thromboembolism: results of the TEV Survey, an Italian epidemiological study].
    Pesavento R; Iori I;
    G Ital Cardiol (Rome); 2017 Mar; 18(3):239-246. PubMed ID: 28398382
    [TBL] [Abstract][Full Text] [Related]  

  • 53. After failure with acenocoumarol, rivaroxaban in antiphospholipid syndrome: A report of 2 cases.
    Mateos Rodríguez JJ; Bellido D; Castro D; Portillo Sánchez J; Vanegas R; Núñez García A
    Reumatol Clin (Engl Ed); 2019; 15(5):e33-e35. PubMed ID: 28546102
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effectiveness and Safety of Rivaroxaban Versus Warfarin in Frail Patients with Venous Thromboembolism.
    Coleman CI; Turpie AGG; Bunz TJ; Beyer-Westendorf J
    Am J Med; 2018 Aug; 131(8):933-938.e1. PubMed ID: 29526541
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hospitalizations and Other Health Care Resource Utilization Among Patients with Deep Vein Thrombosis Treated with Rivaroxaban Versus Low-molecular-weight Heparin and Warfarin in the Outpatient Setting.
    Deitelzweig S; Laliberté F; Crivera C; Germain G; Bookhart BK; Olson WH; Schein J; Lefebvre P
    Clin Ther; 2016 Aug; 38(8):1803-1816.e3. PubMed ID: 27491278
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [THE EXPERTS CONSENSUS FOR ANTICOAGULANT THERAPY OF VENOUS THROMBOEMBOLISM IN 2016 YR. SIGNIFICANCE OF THE RIVAROXABAN INVESTIGATIONS PROGRAM FOR CHANGES OF APPROACHES, CONCERNING TREATMENT OF THE DEEP VEINS THROMBOSIS AND PULMONARY THROMBOEMBOLISM].
    Burnayeva SV; Vasilyeva II; Gavrisyuk VK; Gerasimenko SI; Gudz IM; Dzyublik AY; Dzyak GV; Zharinov OI; Kobza II; Kovalev AA; Kolesnik EA; Kostylev MV; Kulik IV; Lutay YM; Mishalov VG; Mishchenko TS; Nikonenko AS; Nikonenko AA; Nikulnikov PI; Parkhomenko AN; Polulyakh MV; Rudenko KV; Skupoy OM; Tatarchuk TF; Todurov BM; Usenko AY; Feshchenko YI; Chernukha IM; Yachnik AI
    Klin Khir; 2017; (3):65-80. PubMed ID: 30277356
    [No Abstract]   [Full Text] [Related]  

  • 57. Health Economic Analysis of Rivaroxaban and Warfarin for Venous Thromboembolism Management in Chinese Patients.
    Fung KP; Chan KH; Ng V; Tsui PT; You JHS
    Cardiovasc Drugs Ther; 2019 Jun; 33(3):331-337. PubMed ID: 30888571
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Indirect comparison and cost-utility of dabigatran etexilate and rivaroxaban in the treatment and extended anticoagulation of venous thromboembolism in a UK setting.
    Jugrin AV; Hösel V; Ustyugova A; De Francesco M; Lamotte M; Sunderland T
    J Med Econ; 2016; 19(1):1-10. PubMed ID: 26390231
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Patient satisfaction after conversion from warfarin to direct oral anticoagulants for patients on extended duration of anticoagulation for venous thromboembolism - The SWAN Study.
    Hendriks T; McGregor S; Rakesh S; Robinson J; Ho KM; Baker R
    PLoS One; 2020; 15(6):e0234048. PubMed ID: 32497116
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Not Available].
    Själander S; Själander A
    Lakartidningen; 2018 Dec; 115():. PubMed ID: 30512136
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.